Pengpeng Xu - Search Results

Year	Number of Results
2011	1
2012	1
2013	3
2014	4
2015	7
2016	8
2017	11
2018	3
2019	12
2020	15
2021	26
2022	25
2023	22
2024	9

1

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.

Shen R, Fu D, Dong L, Zhang MC, Shi Q, Shi ZY, Cheng S, Wang L, Xu PP, Zhao WL. Shen R, et al. Signal Transduct Target Ther. 2023 Apr 10;8(1):145. doi: 10.1038/s41392-023-01358-y. Signal Transduct Target Ther. 2023. PMID: 37032379 Free PMC article.

2

Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma.

Xiong J, Cui BW, Wang N, Dai YT, Zhang H, Wang CF, Zhong HJ, Cheng S, Ou-Yang BS, Hu Y, Zhang X, Xu B, Qian WB, Tao R, Yan F, Hu JD, Hou M, Ma XJ, Wang X, Liu YH, Zhu ZM, Huang XB, Liu L, Wu CY, Huang L, Shen YF, Huang RB, Xu JY, Wang C, Wu DP, Yu L, Li JF, Xu PP, Wang L, Huang JY, Chen SJ, Zhao WL. Xiong J, et al. Cancer Cell. 2020 Mar 16;37(3):403-419.e6. doi: 10.1016/j.ccell.2020.02.005. Cancer Cell. 2020. PMID: 32183952 Free article.

3

Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.

Zhang MC, Tian S, Fu D, Wang L, Cheng S, Yi HM, Jiang XF, Song Q, Zhao Y, He Y, Li JF, Mu RJ, Fang H, Yu H, Xiong H, Li B, Chen SJ, Xu PP, Zhao WL. Zhang MC, et al. Cancer Cell. 2023 Oct 9;41(10):1705-1716.e5. doi: 10.1016/j.ccell.2023.09.004. Epub 2023 Sep 28. Cancer Cell. 2023. PMID: 37774697 Free article.

4

All roads lead to targeted diffuse large B-cell lymphoma approaches.

Xu PP, Huo YJ, Zhao WL. Xu PP, et al. Cancer Cell. 2022 Feb 14;40(2):131-133. doi: 10.1016/j.ccell.2022.01.013. Cancer Cell. 2022. PMID: 35167823 Free article.

5

CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.

Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, Cheng S, Sun XJ, Liu F, Huang JY, Ji MM, Zhao WL. Huang YH, et al. Signal Transduct Target Ther. 2021 Jan 11;6(1):10. doi: 10.1038/s41392-020-00437-8. Signal Transduct Target Ther. 2021. PMID: 33431788 Free PMC article.

6

Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis.

Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, He X, Wang C, Ouyang B, Zhao P, Wang L, Xu P, Cheng S, Wang Z, Zou D, Han L, Zhao W. Lu H, et al. Among authors: xu p. Cell Host Microbe. 2022 Aug 10;30(8):1139-1150.e7. doi: 10.1016/j.chom.2022.07.003. Cell Host Microbe. 2022. PMID: 35952646 Free article.

7

Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.

Sun R, Zhang PP, Weng XQ, Gao XD, Huang CX, Wang L, Hu XX, Xu PP, Cheng L, Jiang L, Fu D, Qu B, Zhao Y, Feng Y, Dou HJ, Zheng Z, Zhao WL. Sun R, et al. Signal Transduct Target Ther. 2022 Mar 18;7(1):80. doi: 10.1038/s41392-022-00895-2. Signal Transduct Target Ther. 2022. PMID: 35301282 Free PMC article.

8

GPCR signaling contributes to immune characteristics of microenvironment and process of EBV-induced lymphomagenesis.

Xiong J, Dai YT, Wang WF, Zhang H, Wang CF, Yin T, Cheng S, Zhong HJ, Yu SH, Jiang L, Wang SY, Fang H, Zhang RH, Zhu Y, Yi HM, Jiang XF, Chen JY, Wang L, Xu PP, Chen SJ, Zhao WL. Xiong J, et al. Sci Bull (Beijing). 2023 Nov 15;68(21):2607-2619. doi: 10.1016/j.scib.2023.09.029. Epub 2023 Sep 22. Sci Bull (Beijing). 2023. PMID: 37798178 Free article.

9

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma.

Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, Cheng S, Zhao Y, Feng Y, Liu Q, Wang L, Zhao WL. Fang Y, et al. Signal Transduct Target Ther. 2023 Oct 6;8(1):381. doi: 10.1038/s41392-023-01626-x. Signal Transduct Target Ther. 2023. PMID: 37798292 Free PMC article.

10

Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.

Shi Q, He Y, Yi HM, Mu RJ, Jiang XF, Fu D, Dong L, Qin W, Xu PP, Cheng S, Song Q, Chen SJ, Wang L, Zhao WL. Shi Q, et al. Cancer Commun (Lond). 2023 Aug;43(8):896-908. doi: 10.1002/cac2.12462. Epub 2023 Jul 4. Cancer Commun (Lond). 2023. PMID: 37403255 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

129 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year